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INTRODUCTION
Mammography is recommended as a screening tool for the 
early detection of breast cancer by various internationally 
recognized guidelines such as those presented by the 
American Cancer Society (ACS) and the U.S. Preventive 
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Service Task Force (USPSTF) (1, 2). In 2009, the USPSTF 
updated its guidelines by raising the recommended age for 
screening mammography to 50 years and older (3) and in 
2015, the ACS also changed its guidelines to women over 
45 years (4). This was due to continuing controversies 
regarding the high false positive and false negative rates 
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seen with screening mammography in younger women in 
their 40s who have dense breasts.
However, in eastern Asian countries such as Korea and 
Japan, the incidence of breast cancer peaks in women in 
their late 40s (5), which is considerably earlier than that 
of western countries, peaking between 60 and 70 years of 
age (6). Therefore, concerns have been raised as to whether 
the USPSTF or ACS guidelines can be directly applied to 
patients in these regions (7). In addition, over 80–90% of 
Korean women in their 40s have heterogeneously dense or 
extremely dense breasts (8, 9), with a low sensitivity on 
mammography (10). Ultrasound (US) has been widely used 
as a supplemental screening tool in Korea to overcome the 
low sensitivity of mammography in dense breasts. Previous 
studies have shown the increased detection of breast 
cancer by supplemental US in women with mammography-
negative dense breasts (11, 12) with one study showing 
the excellent diagnostic performance for US in patients 
with Breast Imaging-Reporting and Data System (BI-RADS) 
category 0 mammography (13). Although a previous study 
has shown excellent survival outcomes (five-year overall 
survival [OS], 100%; disease-free survival [DFS], 98%) for 
women with breast cancers detected by screening US (14), 
there have been no publications regarding the benefits of 
screening US on OS and DFS in breast cancer, compared 
to screening mammography. Some states in the U.S. 
mandate reports on mammogram density and recommend 
supplemental screening tests, such as US, for women with 
dense breasts through breast density notification laws. 
However, in Korea, US is performed in consultation between 
doctors and patients with dense breasts. There are currently 
no guidelines or legislations on the use of screening US in 
women with dense breasts as to date, there is not enough 
evidence to support its use in Korean women aged between 
40 and 49 years.
Therefore, the objective of our study was to compare 
the survival rates of Korean women aged 40 to 49 years 
with breast cancer detected by supplemental screening 
US to those with breast cancer detected by screening 
mammography alone.
MATERIALS AND METHODS
This retrospective study was approved by the Institutional 
Review Board of Severance Hospital. The requirement for 
informed consent was waived due to the retrospective 
nature of the study.
Patients 
We collected the data from 915 females from the breast 
cancer surgery database who had undergone surgery for 
breast cancer between the ages of 40 and 49 at Severance 
Hospital between January 2003 and November 2008. 
The methods used to detect breast lesions were assessed 
through retrospective image reviews, medical records, and 
questionnaires from patients who visited our hospital for 
the first time. Among the initial 915 subjects, patients 
with self-reported symptoms, such as palpable mass or 
nipple discharge, at the time of diagnosis (n = 481) and a 
single patient with cancer detected by positron emission 
tomography (PET) scan (n = 1) were excluded. Patients 
whose detection modality could not be determined as they 
did not undergo mammography or if they did not have 
mammographic images available at the time of review were 
also excluded (n = 77). Finally, patients with a previous 
history of breast cancer surgery (n = 74), bilateral breast 
cancer (n = 39), or lose who were lost during follow-up 
immediately after surgery (n = 3) were excluded. In the 
initial 240 patients, a total of 240 females were included in 
the study population.
Group Classification according to Detection Modality
Based on medical records, radiologic reports, and 
retrospective image reviews, the site of the lesion detected 
by mammogram or US and the actual lesion site proven to 
be a malignancy were correlated and patients were classified 
into the US or mammography group according to their 
detection modality. In our study, detection modality was 
evaluated only for the index tumor. The mean time interval 
between mammography and US was 7.5 days (median: 
0, interquartile range [IQR]: 0–6). If an asymptomatic 
patient had suspicious findings for malignancy on screening 
mammography and was diagnosed pathologically with 
breast cancer afterwards, the patient was included in the 
mammography group. If a patient had negative results on 
screening mammography but had breast cancer detected 
on subsequent supplemental screening US, the patient 
was included in the US group. Two radiologists (with 1 
and 15 years of experience) independently determined the 
detection modality when the mammography category was 
not 1 or 2. In cases of disagreement, the detection modality 
was decided by a consensus.
Data and Statistical Analyses
Demographic and clinical data were collected from our 
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breast cancer database. Patient histories of high-risk 
breast lesions, such as atypical ductal hyperplasia, lobular 
carcinoma in situ, radial scar, and atypical papilloma, was 
also reviewed. Patients were considered to have a family 
history of breast cancer if they had a first-degree relative 
with breast cancer. In our study, females at a high risk 
for breast cancer were defined as patients with a history 
of high-risk breast lesions or a family history of breast 
cancer. Breast parenchymal density on mammograms 
was retrospectively reviewed according to the BI-RADS® 
lexicon by radiologist with 15 years of experience (15). 
Patient histories of neoadjuvant chemotherapy, adjuvant 
chemotherapy, endocrine therapy, and radiation therapy 
were also reviewed. 
The type of surgery each patient underwent was reviewed. 
Breast cancer pathology was determined as invasive 
cancer or ductal carcinoma in situ (DCIS). Cancer stage was 
assessed according to the American Joint Committee on 
Cancer staging system (16). Histologic grade was divided 
into two groups (high grade [grade 3] and not high [grades 
1 and 2]). Tumor size based on the invasive component 
was reviewed. Hormone receptor positivity was defined as 
estrogen receptor and/or progesterone receptor positivity 
(≥ 10% nuclear staining) (17). Human epidermal growth 
factor receptor 2 (HER2) positivity was defined as an 
immunohistochemical (IHC) HER2 score of 3+ or with gene 
amplification by fluorescence in situ hybridization in tumors 
with an IHC HER2 score of 2+ (18). Ki-67 was scored by 
counting the number of cells with positively stained nuclei 
and expressing this value as a percentage of the total tumor 
cells. Recurrence was defined as a relapse of breast cancer 
after initial treatment and was categorized into two groups, 
local recurrence and systemic recurrence. Sites of local 
recurrence included the ipsilateral remnant breast, chest 
wall, lymph nodes inside the breast, axillary, supraclavicular 
fossa, or internal mammary regions. Systemic recurrence was 
defined as any recurrence away from the breast, axillary, 
or internal mammary nodes regions. Local recurrence was 
pathologically confirmed while systemic recurrence was 
diagnosed through biopsy or imaging studies such as PET/
CT, CT or MRI. 
Characteristics were compared between the detection 
modality groups and analyzed using the chi-square test, 
Fisher’s exact test for categorical variables, and the 
independent two-sample test for continuous variables. DFS 
was calculated by subtracting the date of surgery from 
the date of first recurrence or death. For patients with 
no recurrence, the disease-free interval was calculated by 
subtracting the date of surgery from the date of the last 
follow-up. DFS and OS were compared between the detection 
modality groups using the log-rank test and Kaplan-
Meier curves were obtained. Univariable cox regression 
analysis was used to identify factors affecting DFS and OS. 
Multivariable cox regression analysis was used to identify 
independent variables associated with DFS and OS. For rare 
events, Firth’s penalized likelihood logistic regression was 
used. Differences were considered statistically significant if 
the p value was less than 0.05. All statistical analyses were 
performed with SPSS statistics version 25.0 (IBM Corp.) or 
R version 3.5.1 (http://www.r-project.org).
RESULTS
Among the 240 patients with breast cancer, 197 were 
classified into the mammography group and 43 into the US 
group. As for breast density on mammograms, 93.3% (224 
of 240) of all patients had heterogeneously (n = 189) or 
extremely dense breasts (n = 35) and the remaining 6.7% 
(16 of 240) had scattered fibroglandular density, all of 
which were in the mammography group. In the US group, 
all patients had heterogeneously (n = 34) or extremely 
dense breasts (n = 9). The mean follow-up period was 7.4 
years (range, 1.3–12.3 years). The mean follow-up period 
for patients without recurrence was 7.7 years and the mean 
follow-up period for patients with recurrence was 5.6 years. 
There were neither recurrences nor deaths among the 43 
subjects in the US group, while there were 19 recurrences 
(median, 964 days; IQR, 373–1469 days) and 16 deaths 
(median, 2026 days; IQR, 921–3270 days) among the 197 
subjects in the mammography group. For the 19 recurrences, 
there were 3 patients with locoregional recurrence (remnant 
breast, supraclavicular lymph node, and internal mammary 
lymph node), 15 patients with systemic recurrence (lung 
[n = 6], brain [n = 1], liver [n = 7], bone [n = 11], adrenal 
gland [n = 1], and kidney [n = 1]) and 1 patient with both 
local and systemic recurrence (chest wall and mediastinal 
lymph node).
US vs. Mammography: Characteristics and Survival 
There were no statistically significant differences in T and 
N staging between the US and mammography groups. The 
US group had a higher proportion of patients with breast-
conserving surgery (32 of 43, 74.4%), radiation therapy 




(5 of 43, 11.6%) compared to the mammography group 
(37.1%, p < 0.001; 46.2%, p < 0.001; 3.6%, p = 0.045; 
respectively) (Table 1, Supplementary Table 1). The US 
group showed a significantly higher DFS rate compared 
to the mammography group (5-year DFS: 100%, 90.0%, 
respectively, p = 0.016) (Fig. 1A). The US group tended to 
have a higher OS rate compared to the mammography group 
but without statistical significance (p = 0.058) (Fig. 1B). 
In our study, only 6.7% of all subjects (16 of 240) had non-
dense breasts. In individuals with dense breasts, the US 
group tended to show a higher DFS rate compared to the 
mammography group, with statistical significance (p = 0.017) 
and superior OS compared to the mammography group but 
without statistical significance (p = 0.056).
Factors Associated with DFS
In the univariable analysis, the US group had a lower 
risk of recurrence (hazard ratio [HR], 0.086, p = 0.007) 
compared to the mammography group and patients with a 
larger tumor size and high histologic grade had a higher risk 
of recurrence (HR, 1.577, p = 0.012; HR, 2.789, p = 0.012, 
respectively) compared with those with smaller size and 
not-high histologic grade (Table 2). In the multivariable 
analysis, the US group had a lower risk of recurrence 
Table 1. Demographic Characteristics of the US and Mammography Group
Characteristics Mammography (n = 197) US (n = 43) P
Age (years) 45.2 ± 2.8 45.1 ± 3.1 0.832
Breast disease with high risk for breast cancer 0.497
Absent 185 (93.9) 39 (90.7)
Present 12 (6.1) 4 (9.3)
Family history of breast cancer 0.045
Absent 188 (95.4) 38 (81.4)
Present 7 (3.6) 5 (11.6)
N/A 2 (1.0) 0 (0)
Breast density 0.084
Non-dense breast 16 (8.1) 0 (0)
Dense breast 181 (91.9) 43 (100)
Mammography finding < 0.001
Mass only 101 (51.3) 0 (0)
Calcification with/without mass 96 (48.7) 0 (0)
Negative 0 (0) 43 (100)
N/A = not available, US = ultrasound
Fig. 1. DFS and OS (US vs. mammography). 
DFS (A) and OS (B) between the US and mammography group (p = 0.016 and 0.058, respectively). DFS = disease-free survival, OS = overall 
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Univariable Analysis Multivariable Analysis
Hazard Ratio P Hazard Ratio P
Age (years) 1.071 (0.925–1.240) 0.361
Detection modality
Mammography (ref.) 197
US 43 0.086 (0.001–0.613) 0.007 0.097 (0.001–0.705) 0.014
Breast disease with high risk for breast cancer
Absent (ref.) 224
Present 16 0.259 (0.002–1.852) 0.231
Family history of breast cancer
Absent (ref.) 226
Present 12 0.832 (0.112–6.173) 0.857
Surgery type
Breast-conserving surgery (ref.) 105
Total mastectomy 135 0.887 (0.396–1.984) 0.770
Invasiveness
Non-invasive (ref.) 51
Invasive 189 1.916 (0.571–6.423) 0.292
Tumor size (cm) 240 1.577 (1.107–2.246) 0.012 0.975 (0.637–1.443) 0.902
T stage
T0 (ref.) 51
T1 141 1.468 (0.414–5.201) 0.552






N1 36 1.285 (0.426–3.872) 0.656
N2 14 2.947 (0.853–10.187) 0.088
N3 7 3.958 (0.902–17.365) 0.068
Histology grade
Not-high (ref.) 173
High 67 2.789 (1.252–6.210) < 0.012 2.457 (1.108–5.451) 0.027
Chemotherapy
Absent (ref.) 113
Present 127 2.102 (0.870–5.077) 0.099
Endocrine therapy
Absent (ref.) 66
Present 173 0.913 (0.377–2.213) 0.840
Radiation therapy
Absent (ref.) 114
Present 126 1.870 (0.799–4.377) 0.149
Estrogen receptor
Negative (ref.) 66
Positive 168 0.973 (0.402–2.353) 0.951
Progesterone receptor
Negative (ref.) 69
Positive 165 0.858 (0.366–2.011) 0.724
HER2 receptor
Negative (ref.) 154
Positive 47 1.025 (0.375–2.799) 0.961
Unknown 33 0.796 (0.232–2.732) 0.717




(HR, 0.097; 95% confidence interval [CI], 0.001–0.705) 
compared with the mammography group (Table 2). Patients 
with a high histologic grade had a higher risk of recurrence 
(HR, 2.457; 95% CI, 1.108–5.451) compared to those with 
not-high histologic grade (Table 2).
Factors Associated with OS
In the univariable analysis, detection modality, tumor size, 
N stage, histology grade, and a history of chemotherapy 
were associated with OS (HR, 0.134 [US], p = 0.049; HR, 
1.646, p = 0.020; HR, 6.362 [N3], p = 0.019; HR, 2.689, p = 
0.048; HR, 3.637, p = 0.044, respectively) (Table 3). In the 
multivariable analysis, patients with a high histologic grade 
had a higher risk of death (HR, 2.820; 95% CI, 1.056–7.524, 
p = 0.039) compared to those with not-high histologic 
grade. The US group had a lower tendency of death but 
without statistical significance (HR, 0.155, p = 0.077).
DISCUSSION
Due to the lower sensitivity of screening mammography 
in dense breasts, the need for an adjuvant screening tool 
has been recognized and US has been discussed as a 
promising adjunctive screening modality (19). Recently, 
the Japan Strategic Anti-cancer Randomized Trial showed 
a lower incidence of interval cancer when supplemental 
US was performed compared to when only screening 
mammography was performed (20). However, there have 
been very few studies on the survival benefits of screening 
US for breast cancer, despite US being widely used as a 
supportive screening tool in Asia (21, 22). To the best 
of our knowledge, our study is the first to evaluate the 
survival benefit of detecting breast cancers by adjunctive 
screening US in comparison to mammography alone and 
we were able to show improved DFS with screening US (p = 
0.016) compared to screening mammography. A previous 
study suggested that avoiding local recurrence for 5 years is 
important in improving patient survival and that doing so is 
of comparable relevance to 15-year breast cancer mortality 
(23). In our study, despite the excellent 5-year DFS seen 
in the US group, OS did not significantly differ between 
the two groups (p = 0.058). However, considering previous 
research (23), we can speculate that patients who did not 
develop a recurrence within 5 years of the original breast 
cancer will potentially benefit in OS in a future study with 
more than 15 years of follow-up.
The sensitivity of screening mammography is dependent 
on breast density (24) and nearly 80% of Korean females 
in their 40s have either heterogeneously or extremely 
dense breasts (25). In our study, 93.3% of all subjects 
had dense breasts on mammography, which is a higher 
proportion than in the general population. The reason for 
the high proportion of dense breasts was that the study 
was made up of only patients with breast cancer. A previous 
matched study in Korea showed that patients with breast 
cancer were 10% more likely to have dense breasts than 
a matched healthy subject (26). Breast cancer has been 
found to peak in Korean females in their late 40s, which is 
considerably earlier than in western females (5). Patients 
diagnosed with breast cancer before the age of 49 have 
shown higher death rates from breast cancer compared to 
patients diagnosed after age of 49 (27). Therefore, any 
limitations mammography has related to dense breasts 
can be magnified or more critical in Asian females of this 
age group due to the prevalence of dense breasts in this 
population.
In our study, 78–86% of breast cancer cases were T0 or T1 
in size in both groups, consistent with the screened group 
in a previous study (28). Although there was no difference 
in T and N stage between the two groups, the US group 
tended to have a higher proportion of tumors with not-high 
histologic grade than the mammography group. Differences 
in histologic grade between the two groups may affect 
survival. Our study found that patients aged 40–49 years 
who were diagnosed with breast cancer by supplemental 
screening US had higher rates of breast-conserving surgery 
than patients diagnosed by screening mammography, 
although cancer stages were not significantly different 
between the two groups. This may be due to the presence 
of calcifications. In our study, almost half (48.7%) of the 
patients in the mammography group had calcifications. 
Since calcifications are a representative finding of DCIS, 
breast cancers with calcifications on mammography are 
likely to have an additional DCIS component, which 
is not included in tumor size. Considering that breast 
cancer detected by mammography are more likely to have 
calcifications and that calcifications are likely to indicate 
additional DCIS components, there is a high chance of total 
mastectomy. The frequency of radiation therapy was higher 
in the US group than in the mammography group due to 
patients in the US group undergoing breast-conserving 
surgery more frequently.
Our study has a few limitations. Firstly, as this is a 
retrospective and single center study, there were limitations 
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Univariable Analysis Multivariable Analysis
Hazard Ratio P Hazard Ratio P
Age (years) 1.074 (0.896–1.288) 0.439
Detection modality
Mammography (ref.) 197 0.049 0.155 (0.001–1.162) 0.077
US 43 0.134 (0.001–0.992)
Breast disease with high risk for breast cancer
Absent (ref.) 224
Present 16 0.376 (0.003–2.775) 0.423
Family history of breast cancer
Absent (ref.) 226
Present 12 1.304 (0.171–9.919) 0.798
Surgery type
Breast-conserving surgery (ref.) 105
Total mastectomy 135 0.936 (0.347–2.525) 0.896
Invasiveness
Non-invasive (ref.) 51
Invasive 189 1.931 (0.439–8.495) 0.384
Tumor size (cm) 240 1.646 (1.081–2.505) 0.020 1.040 (0.641–1.641) 0.868
T stage
T0 (ref.) 51
T1 141 1.311 (0.272–6.310) 0.736





N1 36 1.548 (0.419–5.723) 0.512 0.832 (0.196–2.946) 0.767
N2 14 2.993 (0.645–13.885) 0.161 1.594 (0.290–6.300) 0.549
N3 7 6.362 (1.364–29.670) 0.019 3.393 (0.618–13.456) 0.142
Histology grade
Not-high (ref.) 173
High 67 2.689 (1.008–7.170) 0.048 2.820 (1.056–7.524) 0.039
Chemotherapy
Absent (ref.) 113
Present 127 3.637 (1.034–12.791) 0.044 3.523 (0.987–15.020) 0.053
Endocrine therapy
Absent (ref.) 66
Present 173 0.864 (0.298–2.506) 0.787
Radiation therapy
Absent (ref.) 114
Present 126 2.100 (0.728–6.063) 0.170
Estrogen receptor
Negative (ref.) 66
Positive 168 0.680 (0.246–1.880) 0.458
Progesterone receptor
Negative (ref.) 69
Positive 165 0.979 (0.338–2.830) 0.968
HER2 receptor
Negative (ref.) 154
Positive 47 0.528 (0.118–2.360) 0.403




to the statistical power and to the inclusion and exclusion 
criteria, which may have resulted in selection bias. 
Secondly, although not analyzed for, the early diagnosis of 
breast cancer may have led to seemingly prolonged survival 
(lead time bias). However, our study shows no significant 
difference in T and N stage and tumor size between the two 
groups. Thirdly, our study did not perform follow-ups that 
went on longer than 10 years. Finally, although survival 
analysis that matched patients of the two groups could 
have shown more reliable results, this was not possible due 
to the lack of recurrence or death in the US group. A larger 
study will be needed in the future. In addition, although 
overdiagnosis and overtreatment caused by false-positive 
results in screening mammography and US have become 
major concerns, our study does not address this issue in 
depth. 
In conclusion, our results from a single institution found 
that Korean females between 40 and 49 years of age with 
breast cancer detected by breast US showed excellent 
survival with neither recurrences nor deaths during follow-
up and showed increased survival rates than females with 
breast cancer detected by screening mammography. To 
obtain more reliable results on the survival benefit of breast 
US for the detection of breast cancer, a multi-center trial 
with a larger sample size is required. 
Supplementary Materials
The Data Supplement is available with this article at 
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